Phaseline

Targets › PLMN

PLMN: drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 3; Neurology, Cardiovascular; next expected readout Jun 2028.

Open in Phaseline: the race on PLMN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SupergeneNon-immunogenic recombinant staphylokinase (Fortelyzin®)
Staphylokinase, a plasminogen activator
PLG, PLMNPhase 3Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, AcuteJun 2028

Conditions

Acute Limb Ischemia (1) Pulmonary Embolism (1) Ischemic Stroke, Acute (1)

Modalities

protein or peptide (1)

Companies

Supergene (1)

Related targets

PLG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.